Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders, fibrotic diseases, and inflammatory conditions. This page serves as the definitive source for verified corporate developments, offering investors and researchers timely access to essential information.
Find comprehensive coverage of MNOV's clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on lead candidates MN-166 (ibudilast) and MN-001 (tipelukast), patent developments, and collaborative research initiatives with academic institutions.
Key content categories include clinical program updates, FDA communications, intellectual property announcements, and financial disclosures. All materials are sourced directly from company filings and official statements to ensure accuracy.
Bookmark this page for streamlined tracking of MNOV's progress in developing small-molecule therapeutics. Check regularly for updates on pipeline advancements in ALS, multiple sclerosis, and fibrotic disease research.
MediciNova announced positive results from a secondary analysis of a Phase 2 trial of MN-166 (ibudilast) for treating alcohol use disorder (AUD), published in The American Journal of Drug and Alcohol Abuse. The analysis indicated that participants with elevated C-reactive protein (CRP) levels showed significant improvements in drinking behaviors and neural activation when treated with MN-166. This suggests potential clinical utility for individuals with AUD and high inflammation, highlighting the need for effective treatments.
MediciNova, Inc., a biopharmaceutical company listed on NASDAQ (MNOV), is set to hold one-on-one virtual meetings with investors during the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. CEO Yuichi Iwaki and VP Geoffrey O'Brien will represent the company. Investors can schedule meetings with Lytham Partners.
The company is developing therapies for various diseases, primarily through its lead assets: MN-166 and MN-001, with clinical trials underway for conditions like ALS and idiopathic pulmonary fibrosis.
MediciNova, Inc. announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for treating glioblastoma. This patent is set to expire no earlier than February 2039 and encompasses treatment methods for various glioblastoma types when combined with other drugs like temozolomide. The company is conducting ongoing trials at the Dana-Farber Cancer Institute. Additionally, MN-166 has been granted orphan-drug designation for glioblastoma, highlighting its potential in this aggressive cancer sector.
MediciNova, Inc. has announced the receipt of a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering MN-001 (tipelukast) and its metabolite MN-002. This patent will focus on treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. The patent is expected to expire no earlier than July 2034. In its Phase 2 trial, MN-001 noticeably reduced serum triglycerides. The compound has multiple mechanisms of action and is currently undergoing further clinical trials, including for type 2 diabetes patients with hypertriglyceridemia.
MediciNova (NASDAQ: MNOV) announced collaboration with the University Health Network for the RECLAIM clinical trial aimed at treating Long COVID with MN-166 (ibudilast). This grant-funded trial, led by Dr. Angela M. Cheung, awaits protocol finalization and regulatory review. Long COVID affects 10-30% of COVID-19 survivors, causing persistent symptoms like fatigue and brain fog. MN-166 is in late-stage development for various diseases, including ALS and multiple sclerosis, highlighting MediciNova's commitment to addressing significant health challenges.
MediciNova, a biopharmaceutical company (NASDAQ:MNOV), announced that its abstract, titled “Improvement of Serum Lipid Panel by Tipelukast (MN-001) in Type 2 Diabetes and NAFLD Patients,” has been selected for presentation at the International Diabetes Federation (IDF) 2022 Congress on December 5-8, 2022. The presentation will be led by Chief Medical Officer, Kazuko Matsuda, MD. This study highlights MN-001's effectiveness in improving lipid profiles in NAFLD patients with Type 2 diabetes, showcasing significant results from a Phase 2 trial.
MediciNova, a biopharmaceutical company trading on NASDAQ under the symbol MNOV, announced a Notice of Allowance from the Korean Intellectual Property Office for a patent covering MN-001 (tipelukast) and its metabolite MN-002 for treating various fibrotic diseases. The patent is expected to expire in June 2035 and includes claims for multiple fibrotic conditions like Crohn's Disease and cystic fibrosis. The company believes this patent will enhance the potential value of MN-001, which has demonstrated anti-inflammatory and anti-fibrotic activities in preclinical models.
MediciNova, Inc. has initiated a Phase 2 clinical trial for MN-001 (tipelukast) targeting non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), and hypertriglyceridemia. The trial includes approximately 40 patients aged 21 to 75, randomized to receive either MN-001 or a placebo for 24 weeks. Co-primary endpoints focus on changes in liver fat content and fasting serum triglycerides. Successful trial results may lead to pivotal Phase 3 trials aimed at supporting a New Drug Application (NDA) for MN-001.
MediciNova, a biopharmaceutical company listed on NASDAQ (MNOV), announced the start of a first-in-human clinical study for a new injectable formulation of MN-166 (ibudilast). This formulation aims to provide healthcare providers with more options for administering MN-166, especially in acute settings and precise injection locations. MN-166 has potential applications in treating various diseases, including ALS and multiple sclerosis. The company has a robust pipeline with several late-stage programs, indicating a strong commitment to advancing innovative therapies.
MediciNova announced a contract modification with BARDA to repurpose MN-166 (ibudilast) as a potential treatment for chlorine gas-induced lung damage, extending the project until March 2023. BARDA previously funded proof-of-concept studies for MN-166 as part of their ReDIRECT program, aiming to develop medical countermeasures against chemical threats. MN-166, a small molecule inhibiting inflammatory cytokines, is also in late-stage development for various neurodegenerative diseases and other conditions.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
